Duration of chemotherapy in low-versus high-volume metastatic cancer: Should there be a difference? Maurie Markman Editor’s Commentary 01 April 2004 Pages: 75 - 76
New antiangiogenic agents for renal cell carcinoma: Bevacizumab Ronald M. Bukowski Clinical Trials Report 01 April 2004 Pages: 85 - 86
New antiangiogenic agents for renal cell carcinoma: Interferon alfa and thalidomide Ronald M. Bukowski Clinical Trials Report 01 April 2004 Pages: 86 - 87
Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides Arthur M. Krieg OriginalPaper 01 April 2004 Pages: 88 - 95
Matrix metalloproteinase inhibitors Nithya RamnathPatrick J. Creaven OriginalPaper 01 April 2004 Pages: 96 - 102
Vascular targeting agents Mary Jo PilatJulie McCormickPatricia Mucci LoRusso OriginalPaper 01 April 2004 Pages: 103 - 110
Mammalian target of rapamycin (mTOR) inhibitors Janice P. Dutcher OriginalPaper 01 April 2004 Pages: 111 - 115
Glutathione analogues in cancer treatment David HamiltonGerald Batist OriginalPaper 01 April 2004 Pages: 116 - 122
Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents Yun DaiSteven Grant OriginalPaper 01 April 2004 Pages: 123 - 130
Surgical reconstruction in patients with cancer of the head and neck Emre Vural OriginalPaper 01 April 2004 Pages: 133 - 140
Epigenetic alterations in head and neck cancer: Prevalence, clinical significance, and implications Chun-Yang Fan OriginalPaper 01 April 2004 Pages: 152 - 161
Assessment of swallowing function in patients with head and neck cancer Alfred A. Simental JrRicardo L. Carrau OriginalPaper 01 April 2004 Pages: 162 - 165